Jardiance vs Lantus: Empagliflozin vs Insulin Glargine Efficacy Compared

How These Two Drugs Work

Jardiance and Lantus lower blood glucose through entirely different mechanisms, and that distinction shapes every clinical outcome that follows.

Empagliflozin (Jardiance) belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. It blocks glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in the urine 1. This mechanism operates independently of insulin secretion, which means the drug does not require functioning beta cells. Because glucose leaves the body through urine rather than being stored, caloric loss accompanies glucose lowering. That caloric deficit accounts for the consistent weight reduction seen in clinical trials.

Insulin glargine (Lantus), by contrast, is a synthetic basal insulin analog with a duration of action spanning roughly 24 hours 2. It replaces or supplements the body's own basal insulin output, suppressing hepatic glucose production overnight and between meals. It works. But it also promotes weight gain by facilitating glucose uptake into adipose tissue and muscle, and it carries an inherent risk of hypoglycemia because it acts regardless of ambient blood glucose levels.

The 2024 American Diabetes Association (ADA) Standards of Care position SGLT2 inhibitors ahead of basal insulin for most patients with type 2 diabetes who have not reached glycemic targets on metformin 3. That recommendation is driven by the cardiovascular and renal benefits demonstrated with SGLT2 inhibitors, a profile that basal insulin has not matched in outcome trials.

HbA1c Reduction: Similar Glucose Lowering, Different Trade-Offs

Both drugs lower HbA1c effectively in type 2 diabetes, with reductions typically falling between 0.7% and 1.0% from baseline in key trials. The difference lies in what accompanies that glucose control.

In a pooled analysis of the EMPA-REG phase III program, empagliflozin 25 mg reduced HbA1c by 0.78% at 24 weeks compared with placebo in treatment-naive and add-on settings 1. Patients with higher baseline HbA1c values saw greater absolute reductions, a common pattern across glucose-lowering drugs.

Insulin glargine consistently produces HbA1c reductions of 0.8% to 1.5%, depending on the titration protocol and baseline HbA1c 4. The ORIGIN trial enrolled patients with dysglycemia (including impaired fasting glucose) and targeted a fasting glucose of <95 mg/dL, achieving a median HbA1c of 6.2% in the glargine arm over 6.2 years of follow-up 2. That is tight control by any standard.

The glycemic potency of insulin glargine is, in theory, higher than empagliflozin's because insulin dosing can be titrated upward without a ceiling. A patient on 80 units of Lantus will achieve more glucose lowering than someone on the fixed 25 mg empagliflozin dose. But that potency comes with costs: each incremental unit of insulin raises hypoglycemia risk and tends to add weight. The ADA notes that SGLT2 inhibitors are preferred when "compelling indications" exist, specifically atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease 3.

Cardiovascular Outcomes: The Defining Separation

This is where the two drugs diverge most dramatically. The cardiovascular evidence gap between empagliflozin and insulin glargine is not subtle.

EMPA-REG OUTCOME (N=7,020) randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin (10 mg or 25 mg) or placebo, added to standard care 1. Over a median 3.1 years, empagliflozin reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14% (HR 0.86 to 95% CI 0.74 to 0.99; P=0.04). The cardiovascular death component drove the result: a 38% relative risk reduction (HR 0.62 to 95% CI 0.49 to 0.77; P<0.001). Hospitalization for heart failure fell by 35% (HR 0.65 to 95% CI 0.50 to 0.85) 1.

Dr. Silvio Inzucchi, then co-chair of the EMPA-REG OUTCOME steering committee, stated: "The cardiovascular mortality benefit was apparent within the first few months and was consistent across subgroups, which was remarkable for a glucose-lowering agent" 1.

The ORIGIN trial (N=12,537) tested early introduction of insulin glargine in people with impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes 2. The result was neutral. Insulin glargine did not increase or decrease the composite rate of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 1.02 to 95% CI 0.94 to 1.11). Cancer incidence was also neutral.

These are not head-to-head data. EMPA-REG OUTCOME enrolled higher-risk patients with established CVD, while ORIGIN enrolled a lower-risk population with early dysglycemia. Direct comparison across trials carries inherent bias. Still, the clinical implication is clear: for a patient with type 2 diabetes and known cardiovascular disease, empagliflozin offers active cardioprotection that insulin glargine does not.

Weight and Body Composition Effects

The weight trajectories of these two drugs move in opposite directions, a distinction that compounds over months and years of treatment.

In EMPA-REG OUTCOME, empagliflozin produced a mean weight reduction of approximately 2 to 3 kg relative to placebo over the study period 1. This weight loss reflects the urinary glucose excretion mechanism: roughly 60 to 80 grams of glucose (240 to 320 kcal) are excreted daily at the empagliflozin 25 mg dose 5. Dual-energy X-ray absorptiometry (DEXA) sub-studies have confirmed that roughly two-thirds of the weight lost with SGLT2 inhibitors comes from fat mass rather than lean mass 5.

Insulin glargine, in contrast, caused a mean weight gain of 1.6 kg over 6.2 years in ORIGIN, compared with no weight change in the standard-care arm 2. In shorter, more intensively titrated studies, weight gain with glargine ranges from 2 to 4 kg over 6 to 12 months 4.

For patients with type 2 diabetes who already carry excess weight (the majority), the weight trajectory of their glucose-lowering regimen matters. A 2022 Endocrine Society clinical practice guideline stated: "Weight gain associated with insulin therapy can worsen insulin resistance and necessitate further dose escalation, creating a cycle that undermines long-term metabolic health" 6.

The practical reality: switching a patient from Lantus to Jardiance can yield a net 4 to 6 kg swing in body weight over 6 to 12 months (2 to 3 kg lost on empagliflozin plus 2 to 3 kg no longer gained from insulin). That magnitude of change can measurably improve insulin sensitivity, blood pressure, and hepatic fat content.

Hypoglycemia Risk

Hypoglycemia separates these drugs as clearly as their cardiovascular profiles.

Empagliflozin carries near-zero risk of hypoglycemia when used without concomitant insulin or sulfonylureas. In EMPA-REG OUTCOME, the rate of confirmed hypoglycemic events (plasma glucose <70 mg/dL) was not significantly different from placebo in patients not receiving background insulin or sulfonylurea therapy 1. The mechanism explains this safety profile: SGLT2 inhibitors reduce glucose reabsorption but do not stimulate insulin release, so the drug's effect diminishes as blood glucose falls into the normal range.

Insulin glargine, by its nature, cannot avoid hypoglycemia entirely. In ORIGIN, severe hypoglycemia (requiring assistance) occurred at a rate of 1.00 event per 100 patient-years in the glargine group versus 0.31 per 100 patient-years in the standard-care group 2. Non-severe confirmed hypoglycemia was substantially higher. These rates were modest by insulin standards because ORIGIN used conservative titration targets, but any rate above zero represents a risk that empagliflozin essentially eliminates.

For older adults, those living alone, or patients with hypoglycemia unawareness, this difference can drive the entire treatment decision.

Renal Outcomes and Kidney Protection

Empagliflozin has demonstrated renal protection beyond glucose control. Lantus has not.

The renal sub-analysis of EMPA-REG OUTCOME showed that empagliflozin reduced incident or worsening nephropathy by 39% (HR 0.61 to 95% CI 0.53 to 0.70; P<0.001) compared with placebo 7. Doubling of serum creatinine fell by 44%. Initiation of renal replacement therapy dropped by 55%, though event numbers were small.

The EMPA-KIDNEY trial (N=6,609) later extended these findings to patients with chronic kidney disease regardless of diabetes status, confirming a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82; P<0.001) 8. The trial was stopped early for efficacy.

Insulin glargine has no demonstrated renoprotective effect independent of glucose control. ORIGIN did not report a dedicated renal composite endpoint, and observational data do not suggest kidney protection from basal insulin beyond what can be attributed to improved glycemia 2.

Current KDIGO 2024 guidelines recommend SGLT2 inhibitors as first-line therapy (alongside metformin or as monotherapy) for patients with type 2 diabetes and an eGFR of 20 mL/min/1.73 m² or above 9. Insulin is reserved for patients who need it to achieve glycemic targets, not for kidney protection.

Blood Pressure and Volume Effects

Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through mild osmotic diuresis and natriuresis 1. This reduction occurs without reflex tachycardia, which suggests a favorable hemodynamic profile. For patients with concurrent hypertension (the majority of those with type 2 diabetes), this is a meaningful secondary benefit.

Insulin glargine does not lower blood pressure. Some data suggest that exogenous insulin may promote sodium retention and mild volume expansion, though the clinical significance of this effect remains debated 10.

The blood pressure differential reinforces the pattern visible across every outcome category: empagliflozin offers a broader metabolic benefit profile, while insulin glargine provides glucose lowering alone.

When Lantus Is the Right Choice

Despite the advantages listed above, insulin glargine remains indispensable for specific patient populations. Not everyone can be treated with an SGLT2 inhibitor alone.

Patients with very high baseline HbA1c values (above 10%) often need insulin to achieve rapid glucose reduction and resolve glucotoxicity. Once glucose levels stabilize, a transition to oral agents including SGLT2 inhibitors may be appropriate. But the initial correction typically requires insulin's titrable potency.

Patients with advanced CKD and an eGFR below 20 mL/min/1.73 m² will see minimal glucose-lowering efficacy from empagliflozin because the drug depends on glomerular filtration to work 9. In this population, insulin remains a first-line option for glycemic control.

Type 1 diabetes or latent autoimmune diabetes in adults (LADA) requires exogenous insulin. SGLT2 inhibitors have been studied as adjuncts in type 1 diabetes, but the FDA has not approved empagliflozin for this indication due to diabetic ketoacidosis risk 11.

Patients already at their target weight or underweight should not be prescribed a drug that promotes further caloric loss. For thin patients with type 2 diabetes (a phenotype more common in South and East Asian populations), insulin may better preserve body composition.

Practical Comparison: Daily Use and Monitoring

Jardiance requires one tablet daily, taken in the morning with or without food. No glucose monitoring is strictly necessary unless the patient is on concomitant insulin or a sulfonylurea. Side effects to monitor include genital mycotic infections (occurring in approximately 6% to 8% of women and 3% to 4% of men), urinary tract infections, and volume depletion in elderly patients or those on loop diuretics 1.

Lantus requires a once-daily subcutaneous injection, typically administered at the same time each day. Dose titration requires regular fasting glucose monitoring, particularly during initiation and dose adjustments. Injection-site reactions, lipohypertrophy at repeatedly used sites, and the need for proper needle disposal add logistical burden. Self-monitoring of blood glucose two to four times weekly is a minimum during titration.

For treatment adherence, oral administration has a measurable advantage. A 2020 meta-analysis in Diabetes Care found that adherence rates for oral glucose-lowering agents exceeded those for injectable therapies by 10 to 15 percentage points at 12 months 12.

Patients prescribed Lantus at 10 IU/day with titration upward by 2 IU every three days to a fasting glucose target of <130 mg/dL should expect to reach a stable dose within 4 to 8 weeks.